European Society For Medical Oncology (ESMO) Congress 2024 Meeting is being held Friday, September 13th through Tuesday, September 17th, with numerous sessions and posters related to minimal residual disease in colorectal cancer.
Highlighted Sessions and Posters
- Transcriptional features of stage IIT4N0/III colon cancer associated with residual disease and ctDNA status after surgery in the PEGASUS trial
- Preliminary analysis in Protector-C study: A prospective, multicenter cohort of utilizing circulating tumor DNA (ctDNA) methylation as postoperative surveillance for colorectal cancer
- Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY
- Predicting the efficacy of neoadjuvant chemoradiotherapy in rectal cancer patients based on dynamic tumor-informed ctDNA-MRD
- Novel clinical decision support (CDS) system optimizing adjuvant chemotherapy (ACT) for colorectal cancer (CRC) by integrating deep learning and circulating tumor DNA (ctDNA) molecular residual disease (MRD): GALAXY histotyping
- Association between copy number aberration and ctDNA MRD in colorectal cancer: CIRCULATE-Japan GALAXY
- Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
